Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review
Cancers · 01.02.2025 · 17 (3) · 480
DOI: 10.3390/cancers17030480 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancers, online erschienen am 01.02.2025. Verfasst von Anca Zgura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, 0200…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tumour mutational burden (TMB) is an emerging biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs) in cancer therapy. While its role is well established in lung cancer and melanoma, its predictive value for breast and prostate cancers remains unclear.
Objective
This systematic review aimed to assess the predictive value of TMB for ICI therapy across four major cancer types—lung, melanoma, breast, and prostate—and to explore factors contributing to the variability in its effectiveness as a biomarker.
Methods
A systematic search and a review of the literature were conducted in accordance with PRISMA guidelines. Studies examining the relationship between TMB levels and clinical outcomes following ICI therapy in the specified cancers were analyzed. The data were synthesized to evaluate TMB’s predictive value and identify gaps in the current research.
Results
High TMB consistently correlated with improved outcomes in lung cancer and melanoma, confirming its predictive utility in these cancers. Conversely, the findings for breast and prostate cancers were inconclusive. The variability in TMB’s predictive value for these cancers suggests the need for complementary biomarkers or refined criteria to enhance its reliability. Methodological inconsistencies in TMB evaluation were also noted as a significant limitation.
Conclusions
TMB serves as a robust biomarker for predicting ICI response in lung cancer and melanoma, but demonstrates limited predictive utility in breast and prostate cancers. Future research should prioritize standardizing TMB assessment protocols and investigating additional biomarkers to improve treatment personalization for these cancer types.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Prof. Dr. Alexandru Trestioreanu Institute of Oncology, 022328 Bucharest, Romania.
- Department of Surgery, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- Department of Urology, "Fundeni" Clinical Institute, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Zitieren
APA
Zgura, A., Chipuc, S., Bacalbasa, N., Haineala, B., Rodica, A., & Sebastian, V. (2025). Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review. Cancers, 17(3), 480. https://doi.org/10.3390/cancers17030480
Vancouver
Zgura A, Chipuc S, Bacalbasa N, Haineala B, Rodica A, Sebastian V. Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review. Cancers. 2025;17(3):480. doi:10.3390/cancers17030480
BibTeX
@article{Zgura2025,
author = {Zgura, Anca and Chipuc, Stefania and Bacalbasa, Nicolae and Haineala, Bogdan and Rodica, Anghel and Sebastian, Vâlcea},
title = {Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review},
journal = {Cancers},
year = {2025},
volume = {17},
number = {3},
pages = {480},
doi = {10.3390/cancers17030480}
}
EUVIMED